← Back to all trials
Recruiting
NCT06933381
Vapocoolant Spray to Reduce Pain With Nexplanon Insertion
Conditions: Reducing Pain With Nexplanon Implant Insertion
Sex: Female
Ages: 14 Years – N/A
Healthy volunteers: Yes
Phase: NA
Enrollment: 70
Sponsor: Queen's Medical Center
Location: Queens Medical Center POB 2 Suite 402 Honolulu Hawaii
Summary
The purpose of this study is to assess if Pain Ease vapocoolant spray decreases pain associated with lidocaine injection during Nexplanon insertion procedures.
Eligibility Criteria
Inclusion Criteria:
* At least 14 years or older
* Undergoing an etonogestrel implant insertion in the arm in POB1 Suite 1004 or POB2 Suite 402
* English speaking
* Able and willing to sign the informed consent form and agree to terms of the study
Exclusion Criteria:
* Required or requested narcotics, anxiolytics, IV sedation, or general anesthesia for the procedure
* Known previous exposure to vapocoolant spray
* Nexplanon removal and reinsertion same day during visit in the same arm
* Contraindications to vapocoolant spray components (ethyl chloride and 1,1,1,3,3-pentafluoropropane/1,1,1,2-tetrafluroethane)
* Unable to provide written, informed consent in English
Source: ClinicalTrials.gov (NCT06933381). StuddyBuddy aggregates publicly available trial information.
